It depends on how you want to balance maximum shareholder value and medical progress. With a big partner with deep pockets, CytoDyn could run and finish trials across all possible indications fairly quickly.

But I agree that it is good that CYDY won't be sold for pennies and Nader will probably get to keep at least half of the cake.